Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYCETIN versus CHLOROMYXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYCETIN versus CHLOROMYXIN.
CHLOROMYCETIN vs CHLOROMYXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
50-100 mg/kg/day IV divided every 6 hours; maximum 4 g/day. Topical: apply to affected area 2-4 times daily.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
None Documented
None Documented
1.5-4 hours in adults; prolonged to 3-7 hours in neonates and 4-12 hours in hepatic impairment; clinical context: dose adjustment required in liver disease.
CHLOROMYXIN is not a recognized drug. No data available.
Renal: 5-10% unchanged; hepatic glucuronidation (90%) followed by renal elimination of metabolites; small biliary excretion (<5%) and fecal elimination.
CHLOROMYXIN is not a recognized drug. No data available.
Category C
Category C
Antibiotic
Antibiotic